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 Abstract 25 
Multiple sclerosis (MS) is a complex autoimmune disease in which T cells and 26 
antibodies damage the myelin sheath in the central nervous system. The aetiology of the 27 
disease is poorly understood.  HLA Class II DR2b (DRB1*1501 β, DRA1*0101 α) is the 28 
strongest genetic risk factor for MS. Genetic remnants of ancient retroviruses, termed human 29 
endogenous retroviruses (HERV) that have been incorporated into the human genome and 30 
Epstein-Barr virus (EBV) infection have also been associated with MS. In silico analyses of 31 
human endogenous retroviral envelope (HERV env) proteins and three myelin proteins 32 
(myelin basic protein, myelin oligodendrocyte glycoprotein and proteolipid protein) that are 33 
principal targets of the autoimmune response showed homologies between potential TH 34 
epitopes within pairs of viral and myelin peptides predicted to bind HLA DR2b. This led to the 35 
proposal that such molecular mimicry may potentially trigger MS. To further test this 36 
hypothesis, the HLA-DR2b binding characteristics of the three myelin proteins and HERV 37 
env peptides as well as in silico predicted peptides from other encephalitogenic brain 38 
proteins and EBV proteins were investigated. Peptides containing potential TH epitopes from 39 
the myelin oligodendrocyte glycoprotein and HERV env previously predicted to bind HLA 40 
DR2b as well as other pertinent potential HLA DR2b-restricted epitopes were shown to be 41 
able to do so in a cell-free binding assay.  Molecular modelling of HLA-DR2b in complex with 42 
high affinity peptides derived from MOG and HERV env proteins highlighted that prominent 43 
surface exposed amino acids, which potentially interface with the T cell receptor, are 44 
conserved.  A structurally similar pair of potential TH epitopes from the EBV protein EBNA1 45 
and β synuclein, a brain protein implicated in MS, were shown to be similarly capable of 46 
binding HLA DR2b molecules. Our findings justify future investigation of TH cell responses to 47 
the candidate peptides.  48 
  49 
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 1. Introduction 52 
Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central 53 
nervous system (CNS) that involves progressive damage to the myelin sheath and axons 54 
leading to neurodegeneration [1 - 3]. Studies on MS patients and experimental allergic 55 
(autoimmune) encephalomyelitis (EAE) in rodents have implicated several CNS proteins 56 
present in oligodendrocytes and myelin, including the myelin basic protein (MBP), myelin 57 
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), as targets of the 58 
autoimmune response in MS [1 - 3]. However, the aetiology of MS is not well understood. 59 
Cells of the innate immune system, CD4+ helper T cells, CD8+ cytotoxic T cells and 60 
autoantibodies are involved in the immunopathology of MS, while CD4+ helper 1 cells (TH1) 61 
among all types of antigen-specific cells, are considered to play the critical role in initiating 62 
the autoimmune process [1 - 3]. Environmental factors, e.g. vitamin D deficiency [4], and 63 
infections especially with Epstein Barr virus (EBV) [1-2, 5-8], have been implicated in 64 
predisposition to MS. Genome-wide association studies demonstrate that the HLA Class II 65 
allele DRB1*1501 β chain variant, which pairs with the relatively invariant DRA1*0101 α 66 
chain to form the HLA DR2b heterodimer in antigen-presenting cells (APCs), is the strongest 67 
genetic risk factor for MS [9]. The production of virions and expression of envelope protein 68 
(env) of a member of the genome-encoded human endogenous retrovirus W-family (HERV-69 
W), termed the MS- associated retrovirus or MSRV [10], has also been implicated in MS [11 70 
- 15]. However, the molecular mechanisms linking TH cells to the genetic elements in the 71 
etiology of MS are not established.  It has been recently hypothesized that epitopes in MSRV 72 
and other HERV family env proteins that cross-react with epitopes in myelin proteins, and 73 
presented by HLA DR2b on APCs to TH1 cells in an inflammatory milieu, provide the 74 
requisite link [16].  75 
Sequence homologies have been demonstrated by BLAST analysis between 76 
MBP, MOG and PLP on one hand and MSRV env on the other [16, 17]. In addition, 77 




(SYN1) [16], another HERV-W family-derived env protein that has evolved to perform an 79 
essential role in forming the syncytiotrophoblast of the placenta [18]. SYN1 is 87% identical 80 
in amino acid sequence to MSRV env [16] and also more distantly related to syncytin-2 81 
(SYN2), another essential fusogenic placental protein derived from a different HERV family 82 
termed HERV-FRD [19]. SYN2 also possesses regions of amino acid sequence similarity 83 
with the three myelin proteins [16]. SYN1 has an additional fusogenic role in the 84 
development of myotubes from myoblasts [20] and possibly osteoclasts [21].   85 
In silico analyses of myelin and HERV env sequences utilizing the Immune 86 
Epitope Data Base (IEDB) [22] to predict HLA DR2b-binding 15mer peptides showed 87 
homologies between potential nonamer TH epitopes within the 15mers from the HERV env 88 
proteins and all three myelin proteins that are predicted to bind to DR2b with high 89 
(IC50<50nM) or intermediate affinity (50nM<IC50<500nM) [16]. Homologies between a 90 
potential nonamer epitope in MOG and those in MSRV env, SYN1 and SYN2 were 91 
particularly significant [16]. Interestingly, some predicted higher affinity DR2b-binding 92 
peptides lie within longer regions of sequence homology between myelin proteins and HERV 93 
env proteins whilst others do not [16]. Since SYN1 and SYN2 have evolved to perform 94 
essential physiological functions in humans, it is possible that TH cells that react with them 95 
may be deleted in the thymus and/or regulatory T cells (Tregs) that dampen an immune 96 
response are selected against them. This may not apply to MSRV env which is not expected 97 
to be normally expressed during development. However MSRV env is expressed within 98 
innate immune cells in an inflammatory situation e.g. during EBV infection [23] and is a 99 
potent stimulant of Toll-like receptor 4 present on macrophages and microglia, leading to 100 
impaired functional maturation of myelin-producing oligodendrocytes [24]. While existing 101 
data are consistent with an initiating role for molecular mimicry between the MSRV env and 102 
myelin proteins in MS, it is unclear whether this extends to the related SYN1 and SYN2 103 




arise from TH cells recognising other myelin epitopes presented by different HLA Class II 105 
molecules as a result of epitope spreading [16, 25].    106 
This study experimentally investigated HLA DR2b binding of 15mer peptides 107 
derived from MBP, MOG, PLP and HERV env proteins earlier identified in silico as 108 
potentially able to bind to HLA DR2b [16]. It also examined the binding to HLA DR2b of 109 
selected peptides from additional CNS proteins reported to be encephalitogenic [1] and 110 
corresponding structurally related peptides present in the three HERV env proteins as well 111 
as EBV proteins that have been described to elicit prominent human CD4+ T cell responses 112 
[2].  The binding of selected peptides with high HLA DR2b binding affinity were additionally 113 
examined by molecular modelling of peptide–HLA DR2b complexes. 114 
 115 
2. Materials and Methods 116 
2.1 Selection of CNS proteins for investigation 117 
The three myelin proteins previously used for in silico analysis of peptides 118 
capable of binding to HLA DR2b [16] and six other potentially encephalitogenic myelin and 119 
oligodendrocyte-associated CNS proteins [1, 26] selected for the present study are listed in 120 
Table 1. 121 
Table 1. CNS proteins selected for investigation 122 
Protein Abbreviation NCBI sequence ID 
Myelin basic protein MBP P02686.3 
Myelin oligodendrocyte glycoprotein MOG Q16653.2 
Phospholipid protein PLP P60201.2 
α, β Crystallin ABP ACP18852 
Myelin-associated oligodendrocyte basic protein MOPB NP_001265251.1 




2’3’ Cyclic nucleotide 3’ phosphodiesterase CNPase P09543 
Myelin-associated glycoprotein MAG AAH53347.1 
β-Synuclein βSYN Q16143 
 123 
2.2 Selection of HERV and EBV proteins for investigation 124 
The three HERV env proteins used previously for predicting HLA DR2b-restricted 125 
peptides through the IEDB in silico procedure [16] and EBV proteins reported to elicit strong 126 
human CD4+ T cell responses [2] were selected for the present study (Table 2).  127 
Table 2. Virus-derived proteins selected for investigation 128 
Virus protein Abbreviation NCBI sequence ID 
HERV-W Syncytin-1 SYN1 Q9UQF0 
HERV-FRD Syncytin-2 SYN2 NP_997465 
HERV-W Multiple sclerosis-associated retrovirus 
envelope protein 
MSRV env AAK18189.1 
Epstein-Barr nuclear antigen 1 EBNA1 YP_401677.1 
Epstein-Barr nuclear antigen 2 EBNA2 ALV83014.1 
Epstein-Barr nuclear antigen 3C EBNA3C CEQ33769.1 
Epstein-Barr virus transactivator BZLF1  BZLF1 CAD53423 
Epstein-Barr virus glycoprotein BZLF2 BZLF2 CEQ33770.1 
Epstein-Barr virus envelope glycoprotein H BXLF2 ATE89094.1 
 129 
2.3 Sequence homologies between CNS and virus-derived proteins 130 
The predicted additional CNS and virus-derived protein coding sequences 131 
obtained from the US National Center for Biotechnology Information (NCBI) data base were 132 
compared by pairwise Basic Local Alignment Search Tool (BLASTp) analysis online using 133 




MOG, PLP and the three HERV env proteins SYN1, SYN2 and MSRV env [16]. Additionally, 135 
every one of the selected CNS proteins shown in Table 1 were individually tested in BLASTp 136 
searches for homology against all non-redundant protein sequences of EBV (human herpes 137 
virus 4 strain B95-8) with NCBI taxonomy ID 10377.  138 
 139 
 140 
2.4 Prediction of peptides potentially binding to HLA DR2b molecules 141 
Prediction of potential peptides binding to HLA DR2b molecules was performed 142 
as previously described [13] using the IEDB analysis resource (www.iedb.org) [22, 27, 28]. 143 
The default peptide length of 15 amino acids was used in the analysis but the results also 144 
show the core nonamer peptides that are expected to bind to the HLA DR2b molecule and 145 
constitute the major portion of the T cell epitope [22, 27, 28]. The Stabilised Matrix Method 146 
(SMM) was used to rank the peptides according to their predicted binding affinities or IC50 147 
which indicates the nM concentration of peptide expected to bind and achieve 50% 148 
saturation of the HLA DR2b molecules [22, 27, 28]. Structural similarities between core 149 
nonamer sequences in 15mer peptides from different proteins that were predicted to bind 150 
HLA DR2b with high or intermediate affinity (IC50<50nM) were determined manually.   151 
 152 
2.5 Determination of the binding affinity and stability of HLA DR2b-peptide complexes 153 
Peptides (15mers) were synthesized by FMOC solid-phase chemistry and quality 154 
checked with matrix assisted laser desorption ionization-time of flight mass spectrometry 155 
(MALDI-TOF MS) by ProImmune (Oxford, UK). Binding characteristics of the peptides to 156 
HLA DR2b were determined by ProImmune using the cell-free REVEAL® MHC class II 157 
binding assay [29]. The REVEAL® assay measured the ability of a peptide to stabilize the 158 




complex by a specific monoclonal antibody [29]. After an initial incubation with peptide for 160 
determining the proportion of MHC molecules binding the peptide (affinity), an additional 161 
measurement was taken after a further 24h incubation at 370C to determine the stability of 162 
binding (stability index). The stability index provides information on whether peptide can be 163 
presented long enough to serve as a T cell epitope. The affinity and stability index were 164 
measured as a percentage of the signal generated by the test peptide in comparison to a 165 
proprietary ProImmune positive control peptide. A well characterised 15mer MBP peptide 166 
with the sequence ENPVVHFFKNIVTPR (hereafter referred to as MBP_3) that is presented 167 
by HLA DR2b and activates CD4+ T cells [30] was chosen as the internal comparative 168 
standard in the assays.  169 
Details of the two sets of 40 peptides from CNS and viral proteins that were 170 
tested in the HLA DR2b binding assays are provided in Supplementary Table S1. The first 171 
set of 40 contained peptides derived from MBP, MOG and PLP and structurally similar 172 
peptides from SYN1 and MSRV env previously identified in silico as being potentially 173 
important for molecular mimicry by the IEDB algorithm [16]. Staggered arrays of 15mers 174 
were used to identify the best binding peptide. The first set also contained a 15mer derived 175 
from EBV DNA polymerase shown to cross-react at the CD4+ T cell level with the control 176 
peptide MBP_3 on presentation by HLA DR2b [30]. A HLA DR2b-restricted MOG epitope 177 
shown previously to stimulate CD4+ T cells to produce IFNγ [31] was also included in the first 178 
set of peptides. Other first set peptides were comprised of closely related signal sequence 179 
peptides of SYN1 and MSRV that encompassed structurally similar nonamers to those in 180 
internal peptides of MBP (including the control peptide MBP_3) and PLP [16], PLP peptides 181 
that contained the nonamer FFFLYGALL that were predicted to strongly bind DR2b [16], and 182 
four MSRV env peptides with the nonamer sequence TSVLVGPLV that exhibited weaker 183 
homology to MOG nonamer IVLPVLGPLV [16]. 184 
The second set of 40 peptides (Supplementary Table S1) were chosen to 185 




binding peptides identified from first set. They were independently synthesised and tested in 187 
REVEAL® binding assays. The second set additionally tested structurally similar pairs of 188 
HLA DR2b-binding peptides identified through IEDB in silico analysis in EBNA1 and HERV 189 
env proteins on one hand and different CNS proteins on the other. They included peptide 190 
pairs from EBNA1 and βSYN, as well as EBNA1 and OSP, that had also been independently 191 
predicted to bind HLA DR2b using a different in silico algorithm [32]. The second set also 192 
included a different MBP peptide reported to be recognised by TH cells in the context of HLA 193 
DR2b [33]. 194 
 195 
2.6 Modelling of 15mer peptides binding to HLA DR2b 196 
Molecular modelling of the HLA DR2b-peptide complexes were performed using 197 
the in silico docking program HADDOCK (high ambiguity driven protein-protein docking) [34]. 198 
Coordinates for the HLA DR2b complex were retrieved from the Protein Data Bank entry 199 
1YMM [35]. Initial coordinates for the DR2b-restricted peptide moieties were extracted from 200 
the crystal structure of the T cell receptor(TCR)/HLA DR2b/MBP_3-peptide complex (entry 201 
1YMM), and then used to build models of peptides with the molecular builder tool in COOT 202 
[36]. Each HLA DR2b-restricted peptide was subsequently subjected to a short 203 
regularisation protocol to ensure that the geometry of the peptide residues conformed to 204 
known bond lengths and angles.  205 
The docking procedure was driven using only ambiguous intermolecular 206 
restraints, which were defined based on previously determined HLA DR2b-peptide 207 
complexes [35. 37, 38]. These structures revealed that the MBP_3 peptide is bound in the 208 
DR2b peptide-binding groove with peptide side chains P1, P4, P6 and P9 occupying pockets 209 
within the groove. Hence residues that line the P1, P4, P6 and P9 pockets of DR2b were 210 
selected as active residues (comprised of E11α, F24α, F32α, W43α, F54α, N62α, D66α, 211 




anchor residue side chains at P1, P4, P6 and P9 were defined as active residues. Passively 213 
involved residues were selected automatically. The 200 structures obtained after water 214 
refinement were analysed and ranked according to their HADDOCK score, a weighted sum 215 
of electrostatic, van der Waals, and restraint energy terms [34]. The lowest energy structure 216 
solutions were visualised and analysed using Pymol (The PyMOL Molecular Graphics 217 
System, Version 1.8 Schrödinger, LLC).   218 
 219 
3. Results 220 
3.1 Sequence homologies between additional selected CNS and EBV or HERV env 221 
proteins 222 
Sequence homologies between the three HERV env proteins and the three 223 
myelin proteins MBP, MOG and PLP observed in BLASTp analysis have been previously 224 
described [16]. BLASTp analysis of the non-redundant protein sequences coded in whole 225 
EBV genome against each of the selected CNS proteins only revealed a weak homology 226 
between α, β crystallin (ABP) and a 53 residue segment of the EBV protein EBNA4 with an 227 
E value of 0.95 (Supplementary Table S2). Pairwise BLASTp analysis of each of the other 228 
selected CNS proteins against the three HERV env proteins demonstrated homologies with 229 
E≤0.5 only between the pairs ABP and SYN2, ABP and MSRV env, and myelin-associated 230 
glycoprotein (MAG) and MSRV env (Supplementary Table S3).  231 
                                               232 
3.2 Structurally related peptides in brain and EBV or HERV env proteins predicted to 233 
bind to HLA DR2b molecules  234 
IEDB analysis of 15mer peptides containing structurally similar  nonamers 235 
predicted to bind to HLA DR2b in MBP, MOG, PLP on one hand and the three HERV env 236 




on the determined structurally similar regions of ABP/SYN2, ABP/MSRV env and 238 
MAG/MSRV env (Supplementary Tables S2 & S3) did not identify 15mer peptides of 239 
potentially high or intermediate affinity of binding to HLA DR2b that also contained 240 
structurally similar nonamer sequences in the three pairs of proteins (Supplementary Table 241 
S4 and reference 16).  242 
Because of the homology observed between ABP and a 53 residue sequence of 243 
EBNA4 and perceived sequence similarities independently predicted between HLA DR2b-244 
binding peptides of EBNA1 and several CNS proteins [32], HLA DR2b binding potential of 245 
15mer peptides from EBNA1 and EBNA4 were also analysed by the IEDB procedure 246 
(Supplementary Table S5). These results when examined together with those in 247 
Supplementary Table S4 and data in reference 16 for HERV env, showed potential pairs of 248 
DR2b-binding peptides of high or intermediate affinity in EBNA1 and OSP, EBNA1 and 249 
βSYN, as well as OSP and MSRV env. These peptides whose sequences are given in 250 
Supplementary Table S6 were subsequently investigated in DR2b binding assays.  251 
  252 
3.3 Experimental binding to HLA DR2b of CNS and viral peptides predicted in silico to 253 
bind HLA DR2b 254 
The results of REVEAL binding assays on the selected peptides (Supplementary 255 
Table S6) showed that the pairs of peptides from MOG and the corresponding three HERV 256 
env proteins containing sequence-related nonamers previously predicted to engage HLA 257 
DR2b [16], and implicated in molecular mimicry, are able to bind HLA DR2b with comparable 258 
binding characteristics to the MBP_3 peptide.  259 
The results also show that some OSP peptides with similar sequences to EBNA1 260 
and MSRV env peptides and with predicted in silico intermediate binding affinity are able to 261 
bind well to HLA DR2b. However, the corresponding structurally related viral peptides did not 262 




sequences. For example, the OSP 15mer STTLRALAPRLMRRV which bound strongly had 264 
five identities in its predicted nonamer DR2b-binding sequence (LRALAPRLM)  to the 265 
corresponding nonamer (LRALLARSH) in two 15mer EBNA1 peptides that however only 266 
showed weak binding to DR2b (Supplementary Table S6).  267 
Peptides from the closely related signal sequences of SYN1 and MSRV that 268 
contained sequence-related nonamers to those in internal peptides of MBP (including the 269 
control peptide MBP_3) and PLP identified in the previous study [16] did not bind strongly to 270 
DR2b in the assays. Only one PLP peptide TASFFFLYGALLLAE that contained the 271 
nonamer sequence FFFLYGALL that was predicted to bind strongly to DR2b [16] was 272 
confirmed to bind strongly to DR2b. Four MSRV env peptides tested containing the nonamer 273 
sequence TSVLVGPLV with weaker homology to the MOG nonamer IVLPVLGPLV did not 274 
bind strongly to DR2b.  275 
Peptides from EBV DNA polymerase and a different MOG region that had been 276 
shown to be presented on DR2b and stimulate CD4+ T cells [30, 31] revealed significant 277 
binding affinity to DR2b in the assay. A MBP peptide (GTLSKIFKLGGRDSR) containing a 278 
putative DR2b-resticted T cell epitope but with a weak predicted IC50 of 940nM based on 279 
IEDB analysis, only demonstrated marginal binding to DR2b. 280 
An exact correlation between the in silico predicted affinity (IC50) and the 281 
experimentally determined affinity by the REVEAL® binding assay for DR2b was not 282 
observed. For example, some PLP peptides with high predicted affinity (IC50<1nM) showed 283 
poor experimental binding while four SYN2 peptides with predicted intermediate affinities 284 
(IC50 of 130 to 149nM) reveal experimental binding comparable to MBP_3 (Supplementary 285 
Table S6).  286 
The details of binding assay results with staggered arrays of significant pairs of 287 




best binding 15mer peptides with nonamers relevant for molecular mimicry grouped together 289 
and compared with the binding of the control MBP peptide are listed in Table 3.  290 
 291 
Table 3. Binding characteristics and Haddock scores of the best pairs of DR2b-292 










1. MOG & 
HERV env 
MOG_4 ITLFVIVPVLGPLVA 151 110 -123.7±2.5 
 MSRV env _5 MPWTLPFLGPLAAII 69 33 -158.1±2.1 
 SYN1_2 MPWILPFLGPLAAII 144 124 -152.5±4.4 
 SYN2_5 KWFSWVLPLTGPLVS 348 181 -137.8±5.3 
      
2. βSYN & 
EBNA1 
β synuclein EKTKEGVLYVGSKTR 91 95 -128.7±3.0 
 EBNA1_2 VAGVFVYGGSKTSLY 118 43 -131.5±5.1 
      
3. Control  MBP_3 ENPVVHFFKNIVTPR 100 100 -163.7±1.6 
Legend to Table 3. Results show the experimentally determined relative affinity and stability 295 
of binding of peptides expressed as a percentage of that observed with the control MBP_3 296 
peptide assigned values of 100. The nonamers sequence predicted to bind in the peptide-297 
binding groove in HLA DR2b are shown in bold letters and underlined. The docking scores 298 
for the HADDOCK-derived lowest energy HLA DR2b-peptide complex models are shown. 299 
 300 
3.4 Molecular models of structurally similar peptides binding to HLA DR2b 301 
Previously identified HLA DR2b-restricted peptides of similar sequences 302 
containing potential TH epitopes from MOG and HERV env were shown to bind HLA DR2b in 303 
the cell-free binding assay. We employed in silico molecular docking strategies to 304 
understand the molecular mechanisms governing binding of the structurally related pairs of 305 
peptides by HLA DR2b and their potential recognition by TCR. To evaluate the feasibility of 306 




ENPVVHFFKNIVTPR to HLA DR2b using HADDOCK and then compared with the available 308 
crystallographic structure (PDB entry 1YMM) [35, 37, 38].  The HLA DR2b-MBP_3 complex 309 
model corresponding to the lowest intermolecular energy (with a HADDOCK score of -163.7) 310 
shows substantial similarity with the published structure in terms of epitope conformation and 311 
docking mode (Figure 1A). Superposition of the MBP_3 peptides derived from the published 312 
and model complex structures show that the main chain conformation is highly conserved 313 
(Figure 1A).  In addition, similar to the published structure, the modelled MBP-3 peptide side 314 
chains at P1, P4, P6 and P9 serve as anchors slotting into the DR2b antigen binding cleft 315 
(Figure 1B&C). Finally, in both the published and modelled complexes, the peptide was held 316 
in the DR2 antigen-binding cleft by a conserved network of hydrogen bonding and non-polar 317 
interactions (Figure 1B&C). These observations justified the use of the HADDOCK docking 318 
approach to generate models of HLA DR2b bound to peptides that are relevant to MS.    319 
To address the molecular mimicry hypothesis we generated models of HLA 320 
DR2b in complex with peptides of the highest affinity derived from MOG and the HERV env 321 
proteins MRSV env, SYN1 and SYN2 that are shown in Table 3. Superposition of the MOG, 322 
MSRV env, SYN1 and SYN2 peptides show that they all adopt a very similar back-bone 323 
conformation (Figure 2A).  Similarly to the control MBP_3 peptide, the P1, P4, P6 and P9 324 
peptide side chain positions serve as anchors inserting into the DR2b antigen binding cleft 325 
(Figure 2B-D). The HLA DR2b-peptide interactions were remarkably conserved between the 326 
different complexes including the control HLA DR2b-MBP_3 complex.  In addition, positions 327 
P-1, P2, P5, and P8 are predicted to be surface exposed in the HADDOCK derived HLA 328 
DR2b-peptide complex models, and therefore potentially involved in binding to the TCR. The 329 
chemical characteristics of these prominent solvent exposed residues were either identical 330 
or structurally related in the relevant pairs of peptides. Taken together, these findings 331 
support the molecular mimicry hypothesis between MOG and HERV env proteins in 332 




To further test the molecular mimicry hypothesis, in silico predicted peptides from 334 
other encephalitogenic brain proteins and EBV proteins were also investigated using 335 
modelling approaches. To address this HADDOCK derived models of HLA DR2b in complex 336 
with the βSYN and EBNA1 peptides shown in Table 3 were generated (Figure 3). These 337 
peptides adopted similar main chain conformations (Figure 3A) and mediated a conserved 338 
network of polar and non-polar interactions with side chains of DR2b (Figure 3 B&C). As with 339 
comparisons between MOG and HERV env proteins, the most prominent surface exposed 340 
residues (at P-1, P2, P5, and P8) and hence potential TCR contacts were mainly conserved 341 
or semi-conservatively substituted between the βSYN and EBNA1 peptide pair. The non- 342 
anchoring residues were however different between the two sets of unrelated peptide pairs 343 
βSYN/EBNA1 and HERV env/MOG, and between each of these and MBP_3 (Table 3 and 344 
Figures 1-3). 345 
The HADDOCK docking scores of the best binding 15mer peptides possessing 346 
the relevant structurally related nonamer pairs are listed in Table 3. The HADDOCK scores 347 
do not correlate with experimentally measured REVEAL® binding affinities or stability indices 348 
for the peptides but the high negative values point towards energetically favourable binding 349 
to DR2b molecules.   350 
 351 
4. Discussion 352 
The molecular mimicry hypothesis proposed previously [16] attempted a unified 353 
explanation for the involvement of CD4+ T cells, HLA-DR2b, HERV env proteins and EBV 354 
infection in the origin of MS. It was supported by the in silico identification of structurally 355 
related pairs of 15mer peptides predicted to bind DR2b in myelin-associated MBP, MOG and 356 
PLP proteins on one hand and HERV env proteins on the other. Homologies between 357 
predicted MOG and HERV env peptides were particularly prominent [16]. The present study 358 




peptides to DR2b as well as generating molecular models of such complexes. It also 360 
investigated the presence of potential DR2b-binding, structurally related, peptide pairs 361 
between HERV env and other CNS proteins as well as between CNS and EBV proteins.  362 
More recent findings are pertinent to the original HERV-related molecular 363 
mimicry hypothesis. EBV, which primarily infects B cells, has been further implicated as a 364 
necessary but not sufficient cause of MS, partly because of its increased and dysregulated 365 
expression in peripheral blood and brain [39 -43]. In addition, antibody titres to EBNA1 have 366 
lately been confirmed to be higher in MS patients compared to controls [44]. EBNA1 has 367 
recently been reported to promote alternative splicing of cellular genes [45]. Since EBNA1 is 368 
widely expressed in EBV infected cells [46], it is intriguing to speculate that its splicing 369 
activity has a role in the trans splicing that has been postulated to produce functional MSRV 370 
env molecules [17]. This adds to the many different mechanisms proposed to explain why 371 
EBV infections are a predisposition for MS [1-2, 5-8]. 372 
HERVs and their putative role in autoimmunity have been lately reviewed [47-49] 373 
and cross-reactive B cell epitopes in MOG and HERV-W env have been documented [50]. 374 
The presence of antibodies to HERV-W env proteins have recently been reported to 375 
differentiate MS from related neurological diseases [51, 52].  376 
Evidence that human GDP-L-fucose synthase peptides are recognised by CD4+ 377 
T cells in the context of HLA DRB3 *0202 in MS patients, and that gut bacterial GDP-L-378 
fucose synthase may be cross-reactive has led to a different proposal for molecular mimicry 379 
in MS [53]. RAS guanyl releasing protein 2 in peripheral memory B cells driving the 380 
proliferation of brain-infiltrating CD4+ TH1 in a HLA DR2b-restricted manner that then 381 
recognise epitopes from the same protein expressed in brain cells has been proposed as 382 
another autoimmune mechanism explaining the association between MS and HLA DR2b 383 




Recent data also suggest that MSRV env is present in microglia associated with 385 
myelinated axons in MS lesions, MSRV env induces inflammatory myelin and neuron 386 
damaging activity in vitro in microglia and that antibodies to MSRV can be neuroprotective in 387 
MS patients [12]. These observations are pertinent to further examining molecular mimicry 388 
between MSRV env and MOG.  389 
The present study suggests that peptides containing nonamers with potential T 390 
cell epitopes in MSRV env, SYN1, SYN2 and MOG have the capacity to bind to HLA DR2b 391 
molecules with comparable affinities and similar binding topology to the well characterised 392 
MBP_3 peptide containing a T cell epitope. The molecular modelling suggests that potential 393 
surface exposed residues that contact TCR are relatively conserved between the MOG and 394 
HERV env peptides which is consistent with the proposed molecular mimicry hypothesis. 395 
The MOG peptides identified that possessed DR2b-binding nonamers that were related in 396 
sequence to those in the three HERV env proteins are located in the predicted C terminal 397 
transmembrane domain of MOG. The corresponding DR2b-binding nonamers of related 398 
amino acid sequence from MSRV env, SYN1 and SYN2 are also sited in predicted 399 
transmembrane domains.  A longer peptide from the transmembrane region of MOG, that 400 
contained the MOG peptide identified in the present work, has independently been shown to 401 
stimulate CD4+ T cells from MS patients to proliferate and secrete IFNγ in a DRB-restricted 402 
manner [55]. It is possible that SYN1 and SYN2 may normally elicit tolerance as they may be 403 
recognised as self-proteins, while MSRV env may function as a foreign protein that can 404 
generate autoimmunity through molecular mimicry under certain circumstances as 405 
previously outlined [16]. Studies on CD4+ T cell response to the peptides identified in this 406 
study will help clarify the potential roles of MOG and the HERV env proteins in the 407 
immunopathogenesis of MS. It is relevant in this context that TCR recognition of MBP_3 408 
bound to DR2b has been shown to involve skewed binding, not typical of TCR binding 409 
foreign peptide-Class II MHC complexes, which can result in potentially weaker interactions 410 




This study did not find evidence for structurally related DR2b-resticted T cell 412 
epitopes between HERV env proteins and other encephalitogenic CNS proteins. This was 413 
also the case in our limited analysis of EBNA1 and EBNA4 against the selected CNS 414 
proteins except for a pair of sequence-related nonamers derived from βSYN and EBNA1 415 
that showed binding affinity and stability comparable to MBP_3 in the REVEAL® assay. 416 
Modelling of the βSYN and EBNA1 peptides with HLA-DR2b revealed binding to the peptide 417 
binding cleft similar to MBP_3 and relative conservation of the surface exposed, potential 418 
TCR contact residues in the two peptides. This suggests the molecular mimicry is possible 419 
between βSYN and EBNA1. It is relevant in this context that βSYN-reactive TH cells have 420 
recently been suggested to be responsible for autoimmune damage to CNS grey matter in 421 
the progressive stage of MS [26]. The possibility that EBNA1 generated, βSYN-reactive TH 422 
cells induce additional autoimmune pathology, after the potential initiation of MS by 423 
molecular mimicry between MOG and HERV env proteins, therefore justifies investigation. 424 
Investigations on other pairs of potential HLA DR2b-binding peptides in EBNA1 and different 425 
CNS proteins predicted independently [32] may also be useful in this context as the present 426 
study was limited to CNS proteins with high encephalitogenic potential and restricted by the 427 
numbers of peptide pairs that could be studied in the HLA DR2b binding assay.  428 
The HLA DR2a molecule is formed by pairing of the DRB5*0101 β chain variant, 429 
whose gene is closely linked to the DRB1*1501 gene in many individuals, with the relatively 430 
non-polymorphic DRA1*0101 α chain. The previous in silico based predictions failed to 431 
identify strong DR2a binding pairs of potential sequence-related TH cell epitopes in HERV 432 
env and myelin proteins MBP, MOG and PLP [16]. However because of the close genetic 433 
linkage of the two β chain loci, the investigation of potential DR2a binding structurally similar 434 
epitopes in the extended set of CNS proteins and EBV or HERV proteins is warranted 435 
because DR2a and DR2b molecules bind complementary sets of peptides through different 436 





5. Conclusions 439 
The results of the cell free HLA DR2b binding assays and molecular modelling 440 
show that sequence-related MOG and HERV env as well as βSYN and EBNA1 peptide 441 
pairs, with each set of pairs containing related potential TH epitopes, are able to bind to HLA 442 
DR2b with similar affinity and conformation to a peptide MBP_3 containing an experimentally 443 
confirmed TH epitope. These findings support the previous in silico analysis-based prediction 444 
that pairs of sequence-related peptides in HERV env proteins and MOG are potential 445 
candidates for a molecular mimicry origin of MS. Kinetic studies of HLA DR2b binding with 446 
highly purified peptides and determination of the crystal structure of HLA DR2b-peptide 447 
complexes can provide more comprehensive binding information in the future. However, 448 
definitive support for molecular mimicry will require detailed studies on CD4+ TH cell 449 
responses to the candidate peptides characterised in this study. Such investigations may 450 
also contribute to the variety of immunomodulatory approaches presently being explored for 451 
treating MS [12, 24, 57 - 63].  452 
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 673 
Figure Legends 674 
Figure 1 Comparison of the HLA DR2b-MBP_3 complex generated by HADDOCK 675 
with the reference structure. (A) Superposition of MBP_3 peptides bound to HLA 676 
DR2b in the reference (cyan) and modelled structures (black). (B) Ribbon 677 
representation of the published crystal structure of HLA DR2b bound to MBP peptide 678 
(MBP_3; ENPVVHFFKNIVTPR) (PDB entry 1YMM). (C) Ribbon representation of the 679 
lowest energy HLA DRb-MBP_3 complex model structure generated by HADDOCK. 680 
The HLA DR2b alpha and beta chains are depicted as pink and blue, respectively. For 681 
clarity only the peptide binding groove is highlighted. The peptide side chains (ball 682 
and stick format) and positions (red) are shown. Peptide residues P1, P4, P6 and P9 683 




chains at P-1, P2, P5 and P8 are surface exposed. HLA-DR2b residues involved in 685 
stabilising peptide binding are also highlighted (ball and stick format). The black 686 
rectangle boxes correspond to the core 9-mer sequence for each peptide. Figure was 687 
generated with Pymol (The PyMOL Molecular Graphics System, Version 1.8 688 
Schrödinger, LLC) 689 
 690 
Figure 2 Comparison of HADDOCK generated models of HLA-DR2b in complex with 691 
peptides derived from myelin (MOG) and HERV W-family (MSRVenv, SYN1 and 692 
SYN2) associated proteins. (A) Superposition of MOG_4 (red), MSRVenv_5 (blue), 693 
SYN1_2 (yellow) and SYN2_5 (green) peptides bound to HLA DR2b. (B) Ribbon 694 
representation of the lowest energy HLA DR2b-MOG_4 complex model structure. (C) 695 
Ribbon representation of the lowest energy HLA DRb-MSRV_5 complex model 696 
structure. (D) Ribbon representation of the lowest energy HLA DR2b-SYN1_2 697 
complex model structure. (E) Ribbon representation of the lowest energy HLA DRb-698 
SYN2_5 complex model structure. The HLA DR2b alpha and beta chains are 699 
depicted as pink and blue, respectively. For clarity only the peptide binding groove is 700 
highlighted. The peptide side chains (ball and stick format) and positions (red) are 701 
shown. Peptide residues P1, P4, P6 and P9 serve as anchor residues which insert 702 
into the antigen binding groove, whereas side chains at P-1, P2, P5 and P8 are 703 
surface exposed. HLA-DR2b residues that contribute to peptide interactions are also 704 
highlighted (ball and stick format). The black rectangle boxes correspond to the core 705 
9-mer sequence for each peptide.   706 
 707 
Figure 3 Comparison of HADDOCK generated models of HLA-DR2b in complex with 708 
peptides derived from a CNS (β-SYN) and an EBV (EBNA1) protein. (A) 709 
Superposition of βSYN (grey) and EBNA1_2 (orange) peptides bound to HLA DR2b. 710 
(B) Ribbon representation of the lowest energy HLA DR2b-βSYN complex model 711 




complex model structure. The HLA DR2b alpha and beta chains are depicted as pink 713 
and blue, respectively. For clarity only the peptide binding groove is highlighted. The 714 
peptide side chains (ball and stick format) and positions (red) are shown. Peptide 715 
residues P1, P4, P6 and P9 serve as anchor residues which slot into the antigen 716 
binding groove, whereas side chains at P-1, P2, P5 and P8 are surface exposed. 717 
HLA-DR2b residues involved in peptide binding are also highlighted (ball and stick 718 
format). The black rectangle boxes correspond to the core 9-mer sequence for each 719 
peptide.   720 
 721 
